Results to your Biomarker

Exposure to
Analytical Technique
Oxidative Stress

Matching services


Tobacco Harm Reduction

With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.

Scientific Contribution

April 2018

Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review

Regulatory Toxicology and Pharmacology, Volume 94, doi: 10.1016/j.yrtph.2018.02.002
March 2018

Analysis of Urinary Eicosanoids by LC-MS/MS Reveals Alterations in the Metabolic Profile after Smoking Cessation

Chemical Research in Toxicology, Volume 31, doi: 10.1021/acs.chemrestox
October 2017

Metabolomic Fingerprinting in Various Body Fluids of a Diet-Controlled Clinical Smoking Cessation Study Using a Validated GC-TOF-MS Metabolomics Platform

Journal of Proteome Research, Volume 16(10), doi: 10.1021/acs.jproteome.7b00128.
January 2018

Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products

Biomarkers, Volume 23(3), doi: 10.1080/1354750X.2017.1419284
February 2012

A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids

Journal of Lipid Research, Volume 53, doi: 10.1194/jlr.D023739
Conference contribution
October 2018

Identifying suitable biomarkers of biological effects (BOBEs) for evaluating reduced risk products

CORESTA Congress 2018, Biomarker Workshop, Kunming, China